Antibody–drug conjugates for cancer

[1]  C. Criscitiello,et al.  Treatment in real-life patients with HER2-positive metastatic breast cancer: What we learn from the KAMILLA trial? , 2019, European journal of cancer.

[2]  G. Mariani,et al.  Resistance mechanisms to anti-HER2 therapies in HER2-positive breast cancer: Current knowledge, new research directions and therapeutic perspectives. , 2019, Critical reviews in oncology/hematology.

[3]  M. Mohty,et al.  Risk Factors for Development of and Progression of Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome. , 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[4]  M. Liedtke,et al.  Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: Final report and long‐term survival follow‐up from the randomized, phase 3 INO‐VATE study , 2019, Cancer.

[5]  P. Fasching,et al.  Trastuzumab Emtansine for Residual Invasive HER2‐Positive Breast Cancer , 2019, The New England journal of medicine.

[6]  A. Iyer,et al.  PDL-1 Antibody Drug Conjugate for Selective Chemo-Guided Immune Modulation of Cancer , 2019, Cancers.

[7]  P. Drake,et al.  Maytansine-bearing antibody-drug conjugates induce in vitro hallmarks of immunogenic cell death selectively in antigen-positive target cells , 2019, Oncoimmunology.

[8]  A. Yermanos,et al.  A novel anti-HER2 anthracycline-based antibody-drug conjugate induces adaptive anti-tumor immunity and potentiates PD-1 blockade in breast cancer , 2019, Journal of Immunotherapy for Cancer.

[9]  W. Stock,et al.  Inotuzumab: from preclinical development to success in B-cell acute lymphoblastic leukemia. , 2019, Blood advances.

[10]  R. Advani,et al.  Brentuximab Vedotin plus Chemotherapy in North American Subjects with Newly Diagnosed Stage III or IV Hodgkin Lymphoma , 2019, Clinical Cancer Research.

[11]  R. Advani,et al.  Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial , 2019, The Lancet.

[12]  Janice M Reichert,et al.  Antibodies to watch in 2019 , 2018, mAbs.

[13]  M. Brown,et al.  APOMAB Antibody–Drug Conjugates Targeting Dead Tumor Cells are Effective In Vivo , 2018, Molecular Cancer Therapeutics.

[14]  Jiang Liu,et al.  FDA Approval Summary: Mylotarg for Treatment of Patients with Relapsed or Refractory CD33-Positive Acute Myeloid Leukemia. , 2018, The oncologist.

[15]  Greg M. Thurber,et al.  Pharmacokinetic and Immunological Considerations for Expanding the Therapeutic Window of Next-Generation Antibody–Drug Conjugates , 2018, BioDrugs.

[16]  H. Dombret,et al.  Gemtuzumab ozogamicin for de novo acute myeloid leukemia: final efficacy and safety updates from the open-label, phase III ALFA-0701 trial , 2018, Haematologica.

[17]  D. Dimitrov,et al.  Tumor stroma‐targeted antibody‐drug conjugate triggers localized anticancer drug release , 2018, The Journal of clinical investigation.

[18]  S. Khan,et al.  Antibody-Drug Conjugates for Cancer Therapy: Chemistry to Clinical Implications , 2018, Pharmaceuticals.

[19]  R. Advani,et al.  Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma. , 2018, Blood.

[20]  Jiang Liu,et al.  FDA Approval: Gemtuzumab Ozogamicin for the Treatment of Adults with Newly Diagnosed CD33-Positive Acute Myeloid Leukemia , 2018, Clinical Cancer Research.

[21]  M. Konopleva,et al.  Inotuzumab ozogamicin in combination with low-intensity chemotherapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukaemia: a single-arm, phase 2 study. , 2018, The Lancet. Oncology.

[22]  J. Connors,et al.  Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin's Lymphoma , 2017, The New England journal of medicine.

[23]  G. A. Lazar,et al.  Next generation antibody drugs: pursuit of the 'high-hanging fruit' , 2017, Nature Reviews Drug Discovery.

[24]  Kristina M. Ilieva,et al.  Antibody structure and engineering considerations for the design and function of Antibody Drug Conjugates (ADCs) , 2017, Oncoimmunology.

[25]  M. Beckmann,et al.  Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial. , 2018, The Lancet. Oncology.

[26]  M. Frigerio,et al.  The Chemical Design and Synthesis of Linkers Used in Antibody Drug Conjugates. , 2018, Current topics in medicinal chemistry.

[27]  W. Stock,et al.  Management of important adverse events associated with inotuzumab ozogamicin: expert panel review , 2018, Bone Marrow Transplantation.

[28]  Aditya Bardia,et al.  Antibody–Drug Conjugates for the Treatment of Solid Tumors: Clinical Experience and Latest Developments , 2017, Targeted Oncology.

[29]  P. Agostinis,et al.  Cell death and immunity in cancer: From danger signals to mimicry of pathogen defense responses , 2017, Immunological reviews.

[30]  M. Brown,et al.  Antibody drug conjugates and bystander killing: is antigen-dependent internalisation required? , 2017, British Journal of Cancer.

[31]  M. Weichenthal,et al.  Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial , 2017, The Lancet.

[32]  Jinbiao Zhan,et al.  Intracellular trafficking of new anticancer therapeutics: antibody–drug conjugates , 2017, Drug design, development and therapy.

[33]  H. Kantarjian,et al.  Hepatic adverse event profile of inotuzumab ozogamicin in adult patients with relapsed or refractory acute lymphoblastic leukaemia: results from the open-label, randomised, phase 3 INO-VATE study. , 2017, The Lancet. Haematology.

[34]  Sung-Bae Kim,et al.  Trastuzumab emtansine versus treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trial. , 2017, The Lancet. Oncology.

[35]  J. Baselga,et al.  Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial. , 2017, The Lancet. Oncology.

[36]  R. Hollingsworth,et al.  Antibody-Drug Conjugates Bearing Pyrrolobenzodiazepine or Tubulysin Payloads Are Immunomodulatory and Synergize with Multiple Immunotherapies. , 2017, Cancer Research.

[37]  J. Ajani,et al.  Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study. , 2017, The Lancet. Oncology.

[38]  C. Dumontet,et al.  Strategies and challenges for the next generation of antibody–drug conjugates , 2017, Nature Reviews Drug Discovery.

[39]  G. Thurston,et al.  Bispecific Antibodies and Antibody–Drug Conjugates (ADCs) Bridging HER2 and Prolactin Receptor Improve Efficacy of HER2 ADCs , 2017, Molecular Cancer Therapeutics.

[40]  E. Perez,et al.  Trastuzumab Emtansine With or Without Pertuzumab Versus Trastuzumab Plus Taxane for Human Epidermal Growth Factor Receptor 2–Positive, Advanced Breast Cancer: Primary Results From the Phase III MARIANNE Study , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[41]  Z. An,et al.  Antibody-drug conjugates: recent advances in conjugation and linker chemistries , 2016, Protein & Cell.

[42]  A. Hagemeijer,et al.  Gemtuzumab Ozogamicin Versus Best Supportive Care in Older Patients With Newly Diagnosed Acute Myeloid Leukemia Unsuitable for Intensive Chemotherapy: Results of the Randomized Phase III EORTC-GIMEMA AML-19 Trial. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[43]  M. Liedtke,et al.  Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia. , 2016, The New England journal of medicine.

[44]  B. Teicher,et al.  Antibody-drug conjugates for cancer therapy. , 2016, The Lancet. Oncology.

[45]  Kim K. Emmerton,et al.  Intracellular Released Payload Influences Potency and Bystander-Killing Effects of Antibody-Drug Conjugates in Preclinical Models. , 2016, Cancer research.

[46]  Feng Jiang,et al.  Linkers Having a Crucial Role in Antibody–Drug Conjugates , 2016, International journal of molecular sciences.

[47]  F. Loganzo,et al.  Combining antibody-drug conjugates and immune-mediated cancer therapy: What to expect? , 2016, Biochemical pharmacology.

[48]  M. Rebelatto,et al.  A Biparatopic HER2-Targeting Antibody-Drug Conjugate Induces Tumor Regression in Primary Models Refractory to or Ineligible for HER2-Targeted Therapy. , 2016, Cancer cell.

[49]  U. Storz.  Antibody-drug conjugates: Intellectual property considerations , 2015, mAbs.

[50]  Christina Peters,et al.  Antibody–drug conjugates as novel anti-cancer chemotherapeutics , 2015, Bioscience reports.

[51]  G. Weiner.  Building better monoclonal antibody-based therapeutics , 2015, Nature Reviews Cancer.

[52]  B. Tomczuk,et al.  Current ADC Linker Chemistry , 2015, Pharmaceutical Research.

[53]  R. Advani,et al.  Anti-CD22 and anti-CD79B antibody drug conjugates are active in different molecular diffuse large B-cell lymphoma subtypes , 2015, Leukemia.

[54]  S. Owen,et al.  Antibody Drug Conjugates: Design and Selection of Linker, Payload and Conjugation Chemistry , 2015, The AAPS Journal.

[55]  Wenyan Zhong,et al.  Evolving Strategies for Target Selection for Antibody-Drug Conjugates , 2015, Pharmaceutical Research.

[56]  E. Estey,et al.  Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials. , 2014, The Lancet. Oncology.

[57]  S. J. Schrieber,et al.  FDA Approval: Ado-Trastuzumab Emtansine for the Treatment of Patients with HER2-Positive Metastatic Breast Cancer , 2014, Clinical Cancer Research.

[58]  N. Munshi,et al.  Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma. , 2014, Blood.

[59]  Peter G Schultz,et al.  A general approach to site-specific antibody drug conjugates , 2014, Proceedings of the National Academy of Sciences.

[60]  Bin Liu,et al.  Methods for site-specific drug conjugation to antibodies , 2013, mAbs.

[61]  R. Pazdur,et al.  First FDA Approval of Dual Anti-HER2 Regimen: Pertuzumab in Combination with Trastuzumab and Docetaxel for HER2-Positive Metastatic Breast Cancer , 2013, Clinical Cancer Research.

[62]  R. Larson,et al.  A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia. , 2013, Blood.

[63]  L. Tchistiakova,et al.  Implications of receptor-mediated endocytosis and intracellular trafficking dynamics in the development of antibody drug conjugates , 2013, mAbs.

[64]  B. Gorovits,et al.  Proposed mechanism of off-target toxicity for antibody–drug conjugates driven by mannose receptor uptake , 2013, Cancer Immunology, Immunotherapy.

[65]  J. Baselga,et al.  Trastuzumab emtansine for HER2-positive advanced breast cancer. , 2012, The New England journal of medicine.

[66]  R. Pazdur,et al.  U.S. Food and Drug Administration Approval Summary: Brentuximab Vedotin for the Treatment of Relapsed Hodgkin Lymphoma or Relapsed Systemic Anaplastic Large-Cell Lymphoma , 2012, Clinical Cancer Research.

[67]  P. Senter,et al.  The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma , 2012, Nature Biotechnology.

[68]  R. Advani,et al.  Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[69]  Scott E Smith,et al.  Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[70]  H. Dombret,et al.  Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study , 2012, The Lancet.

[71]  K. Blackwell,et al.  Understanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[72]  D. Boger,et al.  Fundamental relationships between structure, reactivity, and biological activity for the duocarmycins and CC-1065. , 2009, Journal of medicinal chemistry.

[73]  Edward Chu,et al.  A history of cancer chemotherapy. , 2008, Cancer research.

[74]  R. Pazdur,et al.  FDA drug approval summary: lapatinib in combination with capecitabine for previously treated metastatic breast cancer that overexpresses HER-2. , 2008, The oncologist.

[75]  A. Ullrich,et al.  Paul Ehrlich's magic bullet concept: 100 years of progress , 2008, Nature Reviews Cancer.

[76]  R. Bouabdallah,et al.  High efficacy and safety profile of fractionated doses of Mylotarg as induction therapy in patients with relapsed acute myeloblastic leukemia: a prospective study of the alfa group , 2007, Leukemia.

[77]  P. Carter.  Potent antibody therapeutics by design , 2006, Nature Reviews Immunology.

[78]  Damon L. Meyer,et al.  Effects of Drug Loading on the Antitumor Activity of a Monoclonal Antibody Drug Conjugate , 2004, Clinical Cancer Research.

[79]  Damon L. Meyer,et al.  cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity. , 2003, Blood.

[80]  P. Frost,et al.  Antibody-targeted chemotherapy with immunoconjugates of calicheamicin. , 2003, Current opinion in pharmacology.

[81]  X. H. Chen,et al.  Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[82]  J. Thorson,et al.  Understanding and exploiting nature's chemical arsenal: the past, present and future of calicheamicin research. , 2000, Current pharmaceutical design.

[83]  L. Holmberg,et al.  Prognostic and predictive value of c-erbB-2 overexpression in primary breast cancer, alone and in combination with other prognostic markers. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[84]  W. McGuire,et al.  Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. , 1987, Science.